Graft use in transvaginal pelvic organ prolapse repair: A systematic review

Vivian W. Sung, Rebecca G. Rogers, Joseph I. Schaffer, Ethan M. Balk, Katrin Uhlig, Joseph Lau, Husam Abed, Thomas L. Wheeler, Michelle Y. Morrill, Jeffrey L. Clemons, David D. Rahn, James C. Lukban, Lior Lowenstein, Kimberly Kenton, Stephen B. Young

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the anatomic and symptomatic efficacy of graft use in transvaginal prolapse repair and to estimate the rates and describe the spectrum of adverse events associated with graft use. DATA SOURCES: Eligible studies, published between 1950 and November 27, 2007, were retrieved through Medline and bibliography searches. METHODS OF STUDY SELECTION: To assess anatomic and symptomatic efficacy of graft use, we used transvaginal prolapse repair studies that compared graft use with either native tissue repair or repair with a different graft. To estimate rates of adverse events from graft use, all comparative studies and case series with at least 30 participants were included. For spectrum of adverse events, all study designs were included. TABULATION, INTEGRATION AND RESULTS: Eligible studies were extracted onto standardized forms by one reviewer and confirmed by a second reviewer. Comparative studies were classified by vaginal compartment (anterior, posterior, apical, or multiple), graft type (biologic, synthetic-absorbable, synthetic nonabsorbable) and outcome (anatomic, symptomatic). We found 16 comparative studies, including six randomized trials, 37 noncomparative studies with at least 30 women, 11 case series with fewer than 30 women, and 10 case reports of adverse events.One randomized trial and one prospective comparative study evaluating synthetic, nonabsorbable graft use in the anterior compartment reported favorable anatomic and symptomatic outcomes with graft use. Data regarding graft use for posterior and apical compartments or for biologic or synthetic absorbable graft use in the anterior compartment were insufficient to determine efficacy.Rates and spectrum of adverse events associated with graft use included bleeding (0-3%), visceral injury (1-4%), urinary infection (0-19%), graft erosion (0-30%), and fistula (1%). There were insufficient data regarding dyspareunia, sexual, voiding, or defecatory dysfunction. CONCLUSION: Overall, the existing evidence is limited to guide decisions regarding whether to use graft materials in transvaginal prolapse surgery. Adequately powered randomized trials evaluating anatomic and symptomatic efficacy as well as adverse events are needed.

Original languageEnglish (US)
Pages (from-to)1131-1142
Number of pages12
JournalObstetrics and Gynecology
Volume112
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

Pelvic Organ Prolapse
Transplants
Prolapse
Dyspareunia
Bibliography

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Sung, V. W., Rogers, R. G., Schaffer, J. I., Balk, E. M., Uhlig, K., Lau, J., ... Young, S. B. (2008). Graft use in transvaginal pelvic organ prolapse repair: A systematic review. Obstetrics and Gynecology, 112(5), 1131-1142. https://doi.org/10.1097/AOG.0b013e3181898ba9

Graft use in transvaginal pelvic organ prolapse repair : A systematic review. / Sung, Vivian W.; Rogers, Rebecca G.; Schaffer, Joseph I.; Balk, Ethan M.; Uhlig, Katrin; Lau, Joseph; Abed, Husam; Wheeler, Thomas L.; Morrill, Michelle Y.; Clemons, Jeffrey L.; Rahn, David D.; Lukban, James C.; Lowenstein, Lior; Kenton, Kimberly; Young, Stephen B.

In: Obstetrics and Gynecology, Vol. 112, No. 5, 11.2008, p. 1131-1142.

Research output: Contribution to journalArticle

Sung, VW, Rogers, RG, Schaffer, JI, Balk, EM, Uhlig, K, Lau, J, Abed, H, Wheeler, TL, Morrill, MY, Clemons, JL, Rahn, DD, Lukban, JC, Lowenstein, L, Kenton, K & Young, SB 2008, 'Graft use in transvaginal pelvic organ prolapse repair: A systematic review', Obstetrics and Gynecology, vol. 112, no. 5, pp. 1131-1142. https://doi.org/10.1097/AOG.0b013e3181898ba9
Sung, Vivian W. ; Rogers, Rebecca G. ; Schaffer, Joseph I. ; Balk, Ethan M. ; Uhlig, Katrin ; Lau, Joseph ; Abed, Husam ; Wheeler, Thomas L. ; Morrill, Michelle Y. ; Clemons, Jeffrey L. ; Rahn, David D. ; Lukban, James C. ; Lowenstein, Lior ; Kenton, Kimberly ; Young, Stephen B. / Graft use in transvaginal pelvic organ prolapse repair : A systematic review. In: Obstetrics and Gynecology. 2008 ; Vol. 112, No. 5. pp. 1131-1142.
@article{a2630e6ccd1b4745af903895490374cf,
title = "Graft use in transvaginal pelvic organ prolapse repair: A systematic review",
abstract = "OBJECTIVE: To estimate the anatomic and symptomatic efficacy of graft use in transvaginal prolapse repair and to estimate the rates and describe the spectrum of adverse events associated with graft use. DATA SOURCES: Eligible studies, published between 1950 and November 27, 2007, were retrieved through Medline and bibliography searches. METHODS OF STUDY SELECTION: To assess anatomic and symptomatic efficacy of graft use, we used transvaginal prolapse repair studies that compared graft use with either native tissue repair or repair with a different graft. To estimate rates of adverse events from graft use, all comparative studies and case series with at least 30 participants were included. For spectrum of adverse events, all study designs were included. TABULATION, INTEGRATION AND RESULTS: Eligible studies were extracted onto standardized forms by one reviewer and confirmed by a second reviewer. Comparative studies were classified by vaginal compartment (anterior, posterior, apical, or multiple), graft type (biologic, synthetic-absorbable, synthetic nonabsorbable) and outcome (anatomic, symptomatic). We found 16 comparative studies, including six randomized trials, 37 noncomparative studies with at least 30 women, 11 case series with fewer than 30 women, and 10 case reports of adverse events.One randomized trial and one prospective comparative study evaluating synthetic, nonabsorbable graft use in the anterior compartment reported favorable anatomic and symptomatic outcomes with graft use. Data regarding graft use for posterior and apical compartments or for biologic or synthetic absorbable graft use in the anterior compartment were insufficient to determine efficacy.Rates and spectrum of adverse events associated with graft use included bleeding (0-3{\%}), visceral injury (1-4{\%}), urinary infection (0-19{\%}), graft erosion (0-30{\%}), and fistula (1{\%}). There were insufficient data regarding dyspareunia, sexual, voiding, or defecatory dysfunction. CONCLUSION: Overall, the existing evidence is limited to guide decisions regarding whether to use graft materials in transvaginal prolapse surgery. Adequately powered randomized trials evaluating anatomic and symptomatic efficacy as well as adverse events are needed.",
author = "Sung, {Vivian W.} and Rogers, {Rebecca G.} and Schaffer, {Joseph I.} and Balk, {Ethan M.} and Katrin Uhlig and Joseph Lau and Husam Abed and Wheeler, {Thomas L.} and Morrill, {Michelle Y.} and Clemons, {Jeffrey L.} and Rahn, {David D.} and Lukban, {James C.} and Lior Lowenstein and Kimberly Kenton and Young, {Stephen B.}",
year = "2008",
month = "11",
doi = "10.1097/AOG.0b013e3181898ba9",
language = "English (US)",
volume = "112",
pages = "1131--1142",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Graft use in transvaginal pelvic organ prolapse repair

T2 - A systematic review

AU - Sung, Vivian W.

AU - Rogers, Rebecca G.

AU - Schaffer, Joseph I.

AU - Balk, Ethan M.

AU - Uhlig, Katrin

AU - Lau, Joseph

AU - Abed, Husam

AU - Wheeler, Thomas L.

AU - Morrill, Michelle Y.

AU - Clemons, Jeffrey L.

AU - Rahn, David D.

AU - Lukban, James C.

AU - Lowenstein, Lior

AU - Kenton, Kimberly

AU - Young, Stephen B.

PY - 2008/11

Y1 - 2008/11

N2 - OBJECTIVE: To estimate the anatomic and symptomatic efficacy of graft use in transvaginal prolapse repair and to estimate the rates and describe the spectrum of adverse events associated with graft use. DATA SOURCES: Eligible studies, published between 1950 and November 27, 2007, were retrieved through Medline and bibliography searches. METHODS OF STUDY SELECTION: To assess anatomic and symptomatic efficacy of graft use, we used transvaginal prolapse repair studies that compared graft use with either native tissue repair or repair with a different graft. To estimate rates of adverse events from graft use, all comparative studies and case series with at least 30 participants were included. For spectrum of adverse events, all study designs were included. TABULATION, INTEGRATION AND RESULTS: Eligible studies were extracted onto standardized forms by one reviewer and confirmed by a second reviewer. Comparative studies were classified by vaginal compartment (anterior, posterior, apical, or multiple), graft type (biologic, synthetic-absorbable, synthetic nonabsorbable) and outcome (anatomic, symptomatic). We found 16 comparative studies, including six randomized trials, 37 noncomparative studies with at least 30 women, 11 case series with fewer than 30 women, and 10 case reports of adverse events.One randomized trial and one prospective comparative study evaluating synthetic, nonabsorbable graft use in the anterior compartment reported favorable anatomic and symptomatic outcomes with graft use. Data regarding graft use for posterior and apical compartments or for biologic or synthetic absorbable graft use in the anterior compartment were insufficient to determine efficacy.Rates and spectrum of adverse events associated with graft use included bleeding (0-3%), visceral injury (1-4%), urinary infection (0-19%), graft erosion (0-30%), and fistula (1%). There were insufficient data regarding dyspareunia, sexual, voiding, or defecatory dysfunction. CONCLUSION: Overall, the existing evidence is limited to guide decisions regarding whether to use graft materials in transvaginal prolapse surgery. Adequately powered randomized trials evaluating anatomic and symptomatic efficacy as well as adverse events are needed.

AB - OBJECTIVE: To estimate the anatomic and symptomatic efficacy of graft use in transvaginal prolapse repair and to estimate the rates and describe the spectrum of adverse events associated with graft use. DATA SOURCES: Eligible studies, published between 1950 and November 27, 2007, were retrieved through Medline and bibliography searches. METHODS OF STUDY SELECTION: To assess anatomic and symptomatic efficacy of graft use, we used transvaginal prolapse repair studies that compared graft use with either native tissue repair or repair with a different graft. To estimate rates of adverse events from graft use, all comparative studies and case series with at least 30 participants were included. For spectrum of adverse events, all study designs were included. TABULATION, INTEGRATION AND RESULTS: Eligible studies were extracted onto standardized forms by one reviewer and confirmed by a second reviewer. Comparative studies were classified by vaginal compartment (anterior, posterior, apical, or multiple), graft type (biologic, synthetic-absorbable, synthetic nonabsorbable) and outcome (anatomic, symptomatic). We found 16 comparative studies, including six randomized trials, 37 noncomparative studies with at least 30 women, 11 case series with fewer than 30 women, and 10 case reports of adverse events.One randomized trial and one prospective comparative study evaluating synthetic, nonabsorbable graft use in the anterior compartment reported favorable anatomic and symptomatic outcomes with graft use. Data regarding graft use for posterior and apical compartments or for biologic or synthetic absorbable graft use in the anterior compartment were insufficient to determine efficacy.Rates and spectrum of adverse events associated with graft use included bleeding (0-3%), visceral injury (1-4%), urinary infection (0-19%), graft erosion (0-30%), and fistula (1%). There were insufficient data regarding dyspareunia, sexual, voiding, or defecatory dysfunction. CONCLUSION: Overall, the existing evidence is limited to guide decisions regarding whether to use graft materials in transvaginal prolapse surgery. Adequately powered randomized trials evaluating anatomic and symptomatic efficacy as well as adverse events are needed.

UR - http://www.scopus.com/inward/record.url?scp=58149311462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149311462&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e3181898ba9

DO - 10.1097/AOG.0b013e3181898ba9

M3 - Article

C2 - 18978116

AN - SCOPUS:58149311462

VL - 112

SP - 1131

EP - 1142

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 5

ER -